Bruno Paiva

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8127624/publications.pdf

Version: 2024-02-01

226 papers	22,156 citations	13865 67 h-index	9861 141 g-index
232 all docs	232 docs citations	232 times ranked	14412 citing authors

#	Article	IF	Citations
1	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology, The, 2014, 15, e538-e548.	10.7	3,343
2	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology, The, 2016, 17, e328-e346.	10.7	1,866
3	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. Journal of Clinical Oncology, 2015, 33, 2863-2869.	1.6	1,525
4	Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia, 2017, 31, 2094-2103.	7.2	486
5	Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma. New England Journal of Medicine, 2013, 369, 438-447.	27.0	449
6	Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood, 2012, 120, 1589-1596.	1.4	429
7	Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncology, The, 2010, 11, 934-941.	10.7	427
8	Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood, 2008, 112, 4017-4023.	1.4	425
9	Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood, 2014, 123, 3073-3079.	1.4	380
10	Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement. Journal of Clinical Oncology, 2015, 33, 657-664.	1.6	330
11	International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncology, The, 2019, 20, e302-e312.	10.7	290
12	Whole-genome fingerprint of the DNA methylome during human B cell differentiation. Nature Genetics, 2015, 47, 746-756.	21.4	278
13	High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood, 2012, 119, 687-691.	1.4	274
14	Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival. Journal of Clinical Oncology, 2008, 26, 5775-5782.	1.6	263
15	Human peripheral blood Bâ€cell compartments: A crossroad in Bâ€cell traffic. Cytometry Part B - Clinical Cytometry, 2010, 78B, S47-60.	1.5	258
16	New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood, 2015, 125, 3059-3068.	1.4	256
17	Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment. Cancer Cell, 2017, 31, 396-410.	16.8	251
18	Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. Journal of Clinical Oncology, 2017, 35, 2900-2910.	1.6	248

#	Article	IF	Citations
19	Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials. Journal of Clinical Oncology, 2013, 31, 3279-3287.	1.6	238
20	MYD88 L265P is a marker highly characteristic of, but not restricted to, WaldenstrÃ¶mâ€™s macroglobulinemia. Leukemia, 2013, 27, 1722-1728.	7.2	238
21	Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells. Haematologica, 2010, 95, 1016-1020.	3.5	210
22	Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma. Journal of Clinical Oncology, 2011, 29, 1627-1633.	1.6	202
23	A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Advances, 2020, 4, 5988-5999.	5.2	198
24	Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica, 2013, 98, 980-987.	3.5	193
25	Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood, 2011, 118, 529-534.	1.4	183
26	Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. Journal of Hematology and Oncology, 2018, 11, 10.	17.0	181
27	Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nature Medicine, 2018, 24, 1867-1876.	30.7	179
28	Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for <scp>MRD</scp> detection in multiple myeloma. Cytometry Part B - Clinical Cytometry, 2016, 90, 61-72.	1.5	177
29	Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma. Journal of Clinical Oncology, 2020, 38, 784-792.	1.6	175
30	PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. Leukemia, 2015, 29, 2110-2113.	7.2	170
31	Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 801-812.	10.7	162
32	The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma. Clinical Cancer Research, 2019, 25, 3176-3187.	7.0	156
33	Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia, 2014, 28, 391-397.	7.2	155
34	Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Progressionâ€“Related Death. Journal of Clinical Oncology, 2014, 32, 2173-2180.	1.6	150
35	Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood, 2019, 134, 1337-1345.	1.4	148
36	Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry Part B - Clinical Cytometry, 2016, 90, 31-39.	1.5	144

#	Article	IF	Citations
37	Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica, 2005, 90, 1365-72.	3.5	135
38	Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica, 2013, 98, 79-86.	3.5	132
39	Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood, 2013, 122, 3591-3598.	1.4	131
40	Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood, 2016, 127, 3165-3174.	1.4	129
41	The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells. Clinical Cancer Research, 2011, 17, 1692-1700.	7.0	128
42	Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2016, 17, 1127-1136.	10.7	128
43	Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. Journal of Clinical Oncology, 2022, 40, 3406-3418.	1.6	115
44	Genetic Abnormalities and Patterns of Antigenic Expression in Multiple Myeloma. Clinical Cancer Research, 2005, 11, 3661-3667.	7.0	109
45	Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cellâ€related disorders. Cytometry Part B - Clinical Cytometry, 2010, 78B, 239-252.	1.5	109
46	Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies. Nature Communications, 2017, 8, 15424.	12.8	109
47	Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. Cytometry Part B - Clinical Cytometry, 2016, 90, 26-30.	1.5	108
48	Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Haematologica, 2010, 95, 1913-1920.	3.5	101
49	Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. British Journal of Haematology, 2000, 109, 438-446.	2.5	100
50	GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?. Blood, 2014, 124, 1887-1893.	1.4	95
51	Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood, 2019, 133, 1953-1963.	1.4	94
52	Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Haematologica, 2009, 94, 1599-1602.	3.5	92
53	The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Cell Reports, 2017, 19, 218-224.	6.4	92
54	Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma. Frontiers in Immunology, 2018, 9, 2431.	4.8	85

#	Article	IF	Citations
55	Veno-Occlusive Disease of the Liver after High-Dose Cytoreductive Therapy with Busulfan and Melphalan for Autologous Blood Stem Cell Transplantation in Multiple Myeloma Patients. Biology of Blood and Marrow Transplantation, 2007, 13, 1448-1454.	2.0	83
56	Differentiation stage of myeloma plasma cells: biological and clinical significance. Leukemia, 2017, 31, 382-392.	7.2	83
57	Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Blood, 2016, 127, 1896-1906.	1.4	81
58	Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma â€" an IMWG Research Project. Blood Cancer Journal, 2018, 8, 123.	6.2	81
59	The cellular origin and malignant transformation of WaldenstrÃ¶m macroglobulinemia. Blood, 2015, 125, 2370-2380.	1.4	80
60	Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. Blood, 2021, 137, 49-60.	1.4	80
61	A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control. Leukemia, 2013, 27, 2056-2061.	7.2	78
62	Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer Journal, 2021, 11, 24.	6.2	77
63	Multiparameter flow cytometry for the identification of the WaldenstrÃ¶mâ€™s clone in IgM-MGUS and WaldenstrÃ¶mâ€™s Macroglobulinemia: new criteria for differential diagnosis and risk stratification. Leukemia, 2014, 28, 166-173.	7.2	76
64	Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma. Blood, 2020, 136, 199-209.	1.4	76
65	Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma. Leukemia, 2011, 25, 697-706.	7.2	75
66	Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e30-e37.	0.4	75
67	Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer Journal, 2018, 8, 117.	6.2	74
68	Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. Leukemia, 2012, 26, 1862-1869.	7.2	73
69	Long non-coding RNAs discriminate the stages and gene regulatory states of human humoral immune response. Nature Communications, 2019, 10, 821.	12.8	73
70	Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential. Leukemia, 2015, 29, 1186-1194.	7.2	71
71	Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma. Journal of Clinical Oncology, 2013, 31, 247-255.	1.6	69
72	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia, 2021, 35, 18-30.	7.2	69

#	Article	IF	Citations
73	Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis. Blood, 2016, 127, 1151-1162.	1.4	68
74	The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. Blood, 2009, 114, 4369-4372.	1.4	67
75	Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma. Blood, 2014, 124, 1300-1303.	1.4	67
76	Maintenance Treatment and Survival in Patients With Myeloma. JAMA Oncology, 2018, 4, 1389.	7.1	67
77	Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. Blood, 2019, 134, 2218-2222.	1.4	66
78	Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood, 2022, 139, 492-501.	1.4	64
79	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer Journal, 2021, 11, 192.	6.2	62
80	Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. Blood Cancer Journal, 2020, 10, 108.	6.2	60
81	The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis. Blood, 2011, 117, 3613-3616.	1.4	59
82	Double Vs Single Autologous Stem Cell Transplantation After Bortezomib-Based Induction Regimens For Multiple Myeloma: An Integrated Analysis Of Patient-Level Data From Phase European III Studies. Blood, 2013, 122, 767-767.	1.4	56
83	Combination of Intra-Articular and Intraosseous Injections of Platelet Rich Plasma for Severe Knee Osteoarthritis: A Pilot Study. BioMed Research International, 2016, 2016, 1-10.	1.9	55
84	Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. Blood, 2011, 118, 4547-4553.	1.4	53
85	A predictive model for risk of early gradeâ€‰â‰¥â€‰3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. Leukemia, 2018, 32, 1404-1413.	7.2	53
86	Evaluation of minimal residual disease in multiple myeloma patients by fluorescentâ€polymerase chain reaction: the prognostic impact of achieving molecular response. British Journal of Haematology, 2008, 142, 766-774.	2.5	52
87	Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDAâ€NCI roundtable symposium. American Journal of Hematology, 2014, 89, 1159-1160.	4.1	52
88	Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM. Blood, 2016, 127, 420-425.	1.4	51
89	Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. Blood, 2015, 126, 858-862.	1.4	50
90	Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity. Haematologica, 2018, 103, e318-e321.	3.5	50

#	Article	IF	Citations
91	Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. Blood, 2021, 137, 1154-1165.	1.4	49
92	Treatment for patients with newly diagnosed multiple myeloma in 2015. Blood Reviews, 2015, 29, 387-403.	5.7	48
93	Utility of <scp>CD</scp>54, <scp>CD</scp>229, and <scp>CD</scp>319 for the identification of plasma cells in patients with clonal plasma cell diseases. Cytometry Part B - Clinical Cytometry, 2016, 90, 91-100.	1.5	47
94	CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features. Haematologica, 2011, 96, 328-332.	3.5	46
95	Targeting vasculogenesis to prevent progression in multiple myeloma. Leukemia, 2016, 30, 1103-1115.	7.2	46
96	Current applications of multiparameter flow cytometry in plasma cell disorders. Blood Cancer Journal, 2017, 7, e617-e617.	6.2	45
97	Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma. Leukemia, 2017, 31, 1446-1449.	7.2	44
98	Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia. Leukemia, 2018, 32, 874-881.	7.2	44
99	Roadmap to cure multiple myeloma. Cancer Treatment Reviews, 2021, 100, 102284.	7.7	44
100	Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood, 2022, 139, 835-844.	1.4	43
101	Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. Haematologica, 2014, 99, 1114-1122.	3.5	42
102	Is immunotherapy here to stay in multiple myeloma?. Haematologica, 2017, 102, 423-432.	3.5	42
103	Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death. Cancer Discovery, 2021, 11, 1268-1285.	9.4	42
104	Epstein-Barr Virus and the Origin of Myalgic Encephalomyelitis or Chronic Fatigue Syndrome. Frontiers in Immunology, 2021, 12, 656797.	4.8	42
105	The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma. Haematologica, 2015, 100, e53-e55.	3.5	41
106	Is This the Time to Introduce Minimal Residual Disease in Multiple Myeloma Clinical Practice?. Clinical Cancer Research, 2015, 21, 2001-2008.	7.0	41
107	Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination. Leukemia, 2020, 34, 589-603.	7.2	41
108	Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT. Blood Advances, 2017, 1, 1056-1066.	5.2	40

#	Article	IF	Citations
109	Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma. Journal of Clinical Oncology, 2022, 40, 3151-3161.	1.6	40
110	Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. Blood Cancer Journal, 2018, 8, 46.	6.2	39
111	Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis. Blood Cancer Journal, 2021, 11, 34.	6.2	39
112	Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials. Leukemia, 2018, 32, 971-978.	7.2	38
113	Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells. Haematologica, 2013, 98, 279-287.	3.5	36
114	Assessment of minimal residual disease in myeloma and the need for a consensus approach. Cytometry Part B - Clinical Cytometry, 2016, 90, 21-25.	1.5	35
115	EuroFlow Lymphoid Screening Tube (LST) data base for automated identification of blood lymphocyte subsets. Journal of Immunological Methods, 2019, 475, 112662.	1.4	35
116	Singleâ€agent venetoclax induces MRDâ€negative response in relapsed primary plasma cell leukemia with t(11;14). American Journal of Hematology, 2019, 94, E35-E37.	4.1	35
117	Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma. Genome Research, 2020, 30, 1217-1227.	5.5	35
118	CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. Haematologica, 2012, 97, 1110-1114.	3.5	34
119	Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis. Blood, 2016, 127, 3035-3039.	1.4	34
120	Deficient Spindle Assembly Checkpoint in Multiple Myeloma. PLoS ONE, 2011, 6, e27583.	2.5	33
121	Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma. American Journal of Hematology, 2019, 94, 853-861.	4.1	33
122	miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma. Leukemia, 2021, 35, 823-834.	7.2	33
123	Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia. Leukemia, 2021, 35, 2358-2370.	7.2	31
124	Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients. Haematologica, 2011, 96, 468-471.	3.5	29
125	Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia. Leukemia Research, 2016, 40, 1-9.	0.8	29
126	A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation. Leukemia and Lymphoma, 2017, 58, 153-161.	1.3	29

#	Article	IF	Citations
127	Detection of MYD88 L265P Mutation by Real-Time Allele-Specific Oligonucleotide Polymerase Chain Reaction. Applied Immunohistochemistry and Molecular Morphology, 2014, 22, 768-773.	1.2	28
128	Early mortality in multiple myeloma: the timeâ€dependent impact of comorbidity: A populationâ€based study in 621 realâ€life patients. American Journal of Hematology, 2016, 91, 700-704.	4.1	28
129	Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma. Leukemia, 2021, 35, 1438-1450.	7.2	28
130	Clinical applicability and prognostic significance of molecular response assessed by fluorescentâ€<scp>PCR</scp> of immunoglobulin genes in multiple myeloma. Results from a <scp>GEM</scp>/<scp>PETHEMA</scp> study. British Journal of Haematology, 2013, 163, 581-589.	2.5	27
131	Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5â€year followâ€up. British Journal of Haematology, 2015, 171, 344-354.	2.5	26
132	Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma. Leukemia, 2020, 34, 3007-3018.	7.2	26
133	Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. Clinical Cancer Research, 2021, 27, 5195-5212.	7.0	26
134	Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective caseâ€matched study. American Journal of Hematology, 2014, 89, 355-362.	4.1	24
135	Richter transformation driven by Epsteinâ€“Barr virus reactivation during therapyâ€related immunosuppression in chronic lymphocytic leukaemia. Journal of Pathology, 2018, 245, 61-73.	4.5	24
136	Measurable residual disease in multiple myeloma: ready for clinical practice?. Journal of Hematology and Oncology, 2020, 13, 82.	17.0	24
137	Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma. Blood, 2020, 135, 2375-2387.	1.4	24
138	Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138++ and CD138low Subpopulations in Multiple Myeloma Cell Lines. PLoS ONE, 2014, 9, e92378.	2.5	23
139	Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica, 2014, 99, 155-162.	3.5	23
140	Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing. Current Osteoporosis Reports, 2017, 15, 499-506.	3.6	23
141	How to make usage of the standardized EuroFlow 8-color protocols possible for instruments of different manufacturers. Journal of Immunological Methods, 2019, 475, 112388.	1.4	23
142	Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?. Blood, 2021, 138, 1901-1905.	1.4	23
143	Multiparameter Flow Cytometry Evaluation of Plasma Cell DNA Content and Proliferation in 595 Transplant-Eligible Patients with Myeloma Included in the Spanish GEM2000 and GEM2005<65y Trials. American Journal of Pathology, 2012, 181, 1870-1878.	3.8	22
144	Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array. Hematological Oncology, 2017, 35, 746-751.	1.7	22

#	Article	IF	Citations
145	CAR T-Cells in Multiple Myeloma Are Ready for Prime Time. Journal of Clinical Medicine, 2020, 9, 3577.	2.4	21
146	Preneoplastic somatic mutations including MYD88 ^{L265P} in lymphoplasmacytic lymphoma. Science Advances, 2022, 8, eabl4644.	10.3	21
147	Modulation of Synovial Fluid-Derived Mesenchymal Stem Cells by Intra-Articular and Intraosseous Platelet Rich Plasma Administration. Stem Cells International, 2016, 2016, 1-10.	2.5	20
148	Utility of flow cytometry studies in the management of patients with multiple myeloma. Current Opinion in Oncology, 2016, 28, 511-517.	2.4	20
149	Flow Cytometry. Hematology/Oncology Clinics of North America, 2018, 32, 765-775.	2.2	20
150	Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells. OncoImmunology, 2019, 8, e1599636.	4.6	20
151	Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy. HemaSphere, 2019, 3, e300.	2.7	20
152	Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis. Leukemia, 2019, 33, 1256-1267.	7.2	20
153	First-in-Human Phase I Study of ABBV-838, an Antibodyâ€“Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. Clinical Cancer Research, 2020, 26, 2308-2317.	7.0	20
154	Bendamustine, bortezomib and prednisone for the treatment of newly diagnosed multiple myeloma patients: results of a prospective phase 2 Spanish/Pethema trial. Haematologica, 2015, 100, 1096-102.	3.5	19
155	Multiple Myeloma Minimal Residual Disease. Cancer Treatment and Research, 2016, 169, 103-122.	0.5	19
156	BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee. Biology of Blood and Marrow Transplantation, 2018, 24, 641-648.	2.0	19
157	FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology. Blood Advances, 2022, 6, 690-703.	5.2	19
158	Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials. PLoS ONE, 2018, 13, e0203392.	2.5	18
159	Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial. Blood Advances, 2021, 5, 760-770.	5.2	18
160	Impact of Next-Generation Flow (NGF) Minimal Residual Disease (MRD) Monitoring in Multiple Myeloma (MM): Results from the Pethema/GEM2012 Trial. Blood, 2017, 130, 905-905.	1.4	18
161	Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma. Blood Advances, 2022, 6, 3234-3239.	5.2	18
162	Post-Treatment Bone Marrow Residual Disease > 5% by Flow Cytometry Is Highly Predictive of Short Progression-Free and Overall Survival in Patients With WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 168-171.	0.4	17

#	Article	IF	Citations
163	Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?. Haematologica, 2012, 97, 1608-1611.	3.5	17
164	Origin of Waldenstrom's macroglobulinaemia. Best Practice and Research in Clinical Haematology, 2016, 29, 136-147.	1.7	17
165	Characterization of freshly isolated bone marrow mesenchymal stromal cells from healthy donors and patients with multiple myeloma: transcriptional modulation of the microenvironment. Haematologica, 2020, 105, e470-473.	3.5	17
166	Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib + Lenalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3245-3245.	1.4	17
167	Differential Diagnosis of IgM MGUS and WM According to B-Lymphoid Infiltration by Morphology and Flow Cytometry. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 93-95.	0.4	16
168	A phase 3 trial of azacitidine versus a semiâ€intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia. Cancer, 2021, 127, 2003-2014.	4.1	16
169	Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study. Modern Pathology, 2021, 34, 59-69.	5.5	15
170	Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients. Frontiers in Immunology, 2021, 12, 659018.	4.8	14
171	Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. Blood Cancer Journal, 2021, 11, 101.	6.2	14
172	Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment. Blood, 2019, 134, 581-581.	1.4	14
173	A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma. Clinical Cancer Research, 2022, 28, 2598-2609.	7.0	14
174	Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies. Blood Cancer Journal, 2021, 11, 202.	6.2	14
175	Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations. Leukemia, 2014, 28, 1747-1750.	7.2	13
176	Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing. Haematologica, 2018, 103, e544-e548.	3.5	13
177	Immunologic characterization of COVID-19 patients with hematological cancer. Haematologica, 2021, 106, 1457-1460.	3.5	13
178	Expression of p53 protein isoforms predicts survival in patients with multiple myeloma. American Journal of Hematology, 2022, , .	4.1	13
179	Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations. Leukemia Research Reports, 2015, 4, 64-69.	0.4	12
180	MRD in multiple myeloma: does CR really matter?. Blood, 2022, 140, 2423-2428.	1.4	12

#	Article	IF	Citations
181	Engineering Anti-myeloma Responses Using Affinity-Enhanced TCR-Engineered T Cells. Cancer Cell, 2015, 28, 281-283.	16.8	11
182	Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease. Blood, 2019, 133, 2664-2668.	1.4	11
183	Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature. Blood Cancer Journal, 2019, 9, 36.	6.2	11
184	Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development. Blood, 2021, 138, 1583-1589.	1.4	11
185	Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma. Cancers, 2021, 13, 4924.	3.7	11
186	Circulating microRNAs and Their Role in Multiple Myeloma. Non-coding RNA, 2019, 5, 37.	2.6	10
187	Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis. Leukemia, 2021, 35, 245-249.	7.2	10
188	Monocyte Subsets and Serum Inflammatory and Bone-Associated Markers in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma. Cancers, 2021, 13, 1454.	3.7	10
189	Target Expression, Preclinical Activity and Mechanism of Action of EM801: A Novel First-in-Class Bcma T-Cell Bispecific Antibody for the Treatment of Multiple Myeloma. Blood, 2015, 126, 117-117.	1.4	10
190	New Tools for Diagnosis and Monitoring of Multiple Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e313-e318.	3.8	10
191	An N-glycosylation hotspot in immunoglobulin Îº light chains is associated with AL amyloidosis. Leukemia, 2022, 36, 2076-2085.	7.2	10
192	Biological Characterization and Clinical Relevance of Circulating Tumor Cells: Opening the Pandoraâ€™s Box of Multiple Myeloma. Cancers, 2022, 14, 1430.	3.7	9
193	New Tools for Diagnosis and Monitoring of Multiple Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e313-e318.	3.8	8
194	Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role. Leukemia, 2018, 32, 2427-2434.	7.2	8
195	Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma. British Journal of Haematology, 2013, 163, 223-234.	2.5	7
196	Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy. Molecular Cancer Therapeutics, 2014, 13, 504-516.	4.1	7
197	Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial. Cancers, 2020, 12, 3615.	3.7	7
198	Early detection of treatment failure and early rescue intervention in multiple myeloma: time for new approaches. Blood Advances, 2021, 5, 1340-1343.	5.2	7

#	Article	IF	Citations
199	The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial. Cancers, 2021, 13, 2458.	3.7	7
200	B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients. Cancers, 2021, 13, 1704.	3.7	6
201	Transcriptomic Profiling of Circulating Tumor Cells (CTCs) in Multiple Myeloma (MM): A New Model to Understand Disease Dissemination. Blood, 2018, 132, 245-245.	1.4	5
202	Network metaâ€analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant. Hematological Oncology, 2022, 40, 987-998.	1.7	5
203	Use of human pharyngeal and palatine tonsils as a reservoir for the analysis of Bâ€cell ontogeny in 10 paired samples. Clinical Otolaryngology, 2016, 41, 606-611.	1.2	4
204	Immune profiling in diffuse large B-cell lymphoma and mantle cell lymphoma patients treated with autologous hematopoietic cell transplant. Bone Marrow Transplantation, 2020, 55, 77-85.	2.4	4
205	Comparison Of Sequential Vs Alternating Administration Of Bortezomib, Melphalan and Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) In Elderly Patients With Newly Diagnosed Multiple Myeloma (MM) Patients: GEM2010MAS65 Trial. Blood, 2013, 122, 403-403.	1.4	4
206	Next Generation Flow (NGF): A High Sensitive Technique to Detect Circulating Peripheral Blood (PB) Clonal Plasma Cells (cPC) in Patients with Newly Diagnosed of Plasma Cell Neoplasms (PCN). Blood, 2015, 126, 4180-4180.	1.4	4
207	The Current Role of the Heavy/Light Chain Assay in the Diagnosis, Prognosis and Monitoring of Multiple Myeloma: An Evidence-Based Approach. Diagnostics, 2021, 11, 2020.	2.6	4
208	WaldenstrÃ¶mâ€™s Macroglobulinemia Immunophenotype. , 2017, , 21-34.		3
209	Engineering a Humanised Niche to Support Human Haematopoiesis in Mice: Novel Opportunities in Modelling Cancer. Cancers, 2020, 12, 2205.	3.7	3
210	The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma. Transplantation and Cellular Therapy, 2021, 27, 807-816.	1.2	3
211	Absence of Contribution to a Differential Outcome of the Stringent Complete Response IMWG Category Respect to the Conventional CR in Multiple Myeloma. a Validation Analysis Based on the Pethema/GEM2012MENOS65 Phase III Clinical Trial. Blood, 2018, 132, 1943-1943.	1.4	3
212	Minimal Residual Disease in Multiple Myeloma. Hematologic Malignancies, 2018, , 97-109.	0.2	2
213	Prognostic implications of MRD assessment in multiple myeloma patients: comparison of Next-Generation Sequencing and Next-Generation Flow. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e47.	0.4	2
214	Analysis of Immunophenotypic Response (IR) by Multiparameter Flow Cytometry In 516 Myeloma Patients Included In Three Consecutive Spanish Trials. Blood, 2010, 116, 1910-1910.	1.4	2
215	Next Generation Flow (NGF) for High Sensitive Detection of Minimal Residual Disease (MRD) in Multiple Myeloma (MM). Blood, 2015, 126, 367-367.	1.4	2
216	Deconvolution of the hematopoietic stem cell microenvironment reveals a high degree of specialization and conservation. IScience, 2022, 25, 104225.	4.1	2

#	Article	IF	Citations
217	Reply to "Response to "CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype". Haematologica 2012;97(7):1110-1114. Haematologica, 2013, 98, e10-e10.	3.5	1
218	How deep is the myeloma iceberg?. Blood, 2018, 132, 2424-2425.	1.4	1
219	Impact of Treatment on B-Cell Regeneration By Next Generation Flow Cytometry in Patients with Multiple Myeloma. Blood, 2018, 132, 4491-4491.	1.4	1
220	AnÃ¡lisis de subpoblaciones monocitarias en relaciÃ³n con los factores de riesgo cardiovascular. ClÃ¡nica E InvestigaciÃ³n En Arteriosclerosis, 2019, 31, 152-159.	0.8	1
221	Circulating Tumor Cells (CTCs) for Comprehensive and Multiregional Non-Invasive Genetic Characterization of Multiple Myeloma (MM). Blood, 2019, 134, 3064-3064.	1.4	1
222	Landscape and clinical significance of long noncoding <scp>RNAs</scp> involved in multiple myeloma expressed fusion transcripts. American Journal of Hematology, 2022, 97, .	4.1	1
223	Tumor Reduction in Multiple Myeloma: New Concepts for New Therapeutics. Frontiers in Oncology, 2021, 11, 800309.	2.8	1
224	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 1. Hemato, 2020, 1, 10-22.	0.6	0
225	Long-Term Follow-Up of the Gem2010 Trial of Bortezomib-Melphalan-Prednisone and Lenalidomide-Dexamethasone in Elderly, Newly Diagnosed Multiple Myeloma Patients: Impact of Age, High-Risk Cytogenetics and Minimal Residual Disease. SSRN Electronic Journal, 0, , .	0.4	0
226	Immunofixation (IF) in Urine Is Really Necessary to Define Complete Remission in Multiple Myeloma (MM)? a Subanalysis from the Pethema/GEM2012MENOS65 Phase III Clinical Trial. Blood, 2018, 132, 474-474.	1.4	0